No new news today. Management said on the conference call yesterday that FDA was investigating.anyone who knows anything about biotech would know that. This POS will bounce. Mark my words. I will make $$$$ on Monday.
Management's assessment was a hell of a lot rosier than the language used in the FDA advisory. That's always the case of course, but in this case management's language was verging on dishonest. There is no way they will lift this hold on the current trial as per 'confidence' from management. It will remain on the market for 2nd line use, which is good because there isn't much else, but that's not the market that drove this to almost $4B market cap.